Sunday, September 13, 2015 12:23:58 AM
Well EB, you got me looking back at this again re: ImmunoScore. I must have missed this last time, but found this link:
-------------------------------------------------
------------------------------------------------------
From the immune contexture to the Immunoscore:
the role of prognostic and predictive immune markers in cancer
Helen Angell and Jerome Galon
https://www.researchgate.net/profile/Jerome_Galon/publication/236195604_From_the_immune_contexture_to_the_Immunoscore_the_role_of_prognostic_and_predictive_immune_markers_in_cancer/links/00b49528b3b8942dd8000000.pdf
---------------------------------------------------------
Jerome Galon:
https://fr.linkedin.com/pub/jerome-galon/35/b45/9a
.... next, guess who the #1 on the PAV list is? ==> Helen Angell and she works with AstraZeneca so my guess is since Helen is very well aware of Immunoscore that she is in contact with Nikoletta and CEO Steve King is absolutely correct in saying all this data would be very valuable to any Big Pharma.
----------------------------------------------------------
March 24, 2015
French cancer Dx company born after management buyout at Qiagen unit
HalioDx, a new company focused on cancer companion diagnostics, is kicking off operations after a management buyout at Qiagen's ($QGEN) Marseille subsidiary.
The company will comprise Qiagen Marseille's managers and its 75 employees, with CEO Vincent Fert at the helm. HalioDx will develop cancer assays such as Immunoscore, a next-generation test that improves colon cancer prognosis, and will forge collaborations with "key biopharma players" to create immuno-oncology companion diagnostics to predict patient response to several immuno-oncology solid tumor treatments, the company said in a statement.
HalioDx has worldwide licenses on a broad portfolio of patents on immuno-oncology biomarkers, including several immune gene expression signatures. ImmunoScore was recently validated in a large international study, and the company is shooting for CE-mark approval for the test in the next 18 months.
"Considering the strength and scientific value of our worldwide license portfolio, and the need for powerful prognostic and predictive biomarkers in immune-oncology, we are confident we will rapidly bring the Immunoscore into routine clinical practice for colon cancer, and validate innovative predictive immune companion diagnostics for solid tumors," Fert said in a statement. "With these immune-related assays, we will contribute to a new dimension of personalized medicine in oncology, and support clinicians and patients to identify the optimal anti-cancer treatment strategy."
The company recently raised €7.5 million ($8.2 million) in a Series A round, with MI Care, Sham Innovation Santé and Sofipaca contributing funds. HalioDx also counts Qiagen as its first partner, a potentially fruitful collaboration as the company leverages Qiagen's manufacturing and R&D prowess to build its portfolio.
A partnership with HalioDx also stands to benefit Qiagen, as it continues to expand in the field of companion diagnostics through more than 20 collaborative projects. Last year, the company announced it would team up with Novartis ($NVS) to develop tests for the company's drug portfolio. In May, Qiagen said it would join forces with Eli Lilly ($LLY) for the companies' fourth companion diagnostics project, building on the momentum of past collaborations to develop assay panels for cancer. The company recently struck a deal with Astellas Pharma to create companion diagnostics to go along with two of Astellas' cancer drugs.
http://www.fiercediagnostics.com/story/french-cancer-dx-company-born-after-management-buyout-qiagen-unit/2015-03-24
------------------------------------------------------------
2013 - Qiagen acquires Ingenuity Systems,[12] extending the company's product portfolio to provide analysis and interpretation of molecular data, from sample to insight.
2015 - Qiagen acquires AdnaGen’s circulating tumor cell enrichment technology to improve its capabilities in liquid biopsies.[15]
https://en.wikipedia.org/wiki/Qiagen
-----------------------------------------------------------
Circulating Tumor Cell Detection
Characterize disease progression in Cancer for targeted therapies
Circulating tumor cells (CTCs) are a decisive factor for the emergence of metastases – to be identified and analysed in patient’s blood. The molecular characterization of CTCs offers a portrait of the specific disease state over time. The AdnaTest platform offers a diagnostic tool representing a "liquid biopsy".
http://www.adnagen.com/cfscripts/main.cfm
-----------------------------------------------------------
Now for an extra bonus for all those still reading... and whom noticed that Jerome Galon is with INSERM and this is "just" one PS recent article blooming out there.
-------------------------------------------------------------
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!
Recent CDMO News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:50:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:48:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 08:40:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 08:30:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 12:23:26 AM
- Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024 • GlobeNewswire Inc. • 07/02/2024 08:05:04 PM
- Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024 • GlobeNewswire Inc. • 07/01/2024 11:00:21 AM
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
Maybacks Global Entertainment and ZEASN Technology Private Ltd. Sign Global Licensing Agreement • AHRO • Aug 8, 2024 7:00 AM
SANUWAVE Will Host a Conference Call on August 13, 2024 at 8:30 AM (ET) to Present Q2 Financial Results • SNWV • Aug 8, 2024 6:59 AM
Kona Gold Beverage Inc. Signs Letter of Intent with Bemax, Inc. to Sell Kona Gold, LLC • BMXC • Aug 7, 2024 10:00 AM
Btab Ecommerce Group, Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • BBTT • Aug 7, 2024 9:00 AM
Hydromer, Inc. Announces Preliminary Unaudited Second Quarter 2024 Financial Results and Provides Business Update • HYDI • Aug 7, 2024 8:52 AM
North Bay Resources Announces Mt. Vernon Gold Mine Startup, Sierra County, California • NBRI • Aug 5, 2024 9:00 AM